Description |
TRC051384 is a heat shock protein 70 (HSP70) inducer.
|
Related Catalog |
|
Target |
HSP70
|
In Vitro |
TRC051384, dose dependently induces HSP70B mRNA by several hundred folds in both HeLa and rat primary mixed neurons. Treatment with TRC051384 results in significant dose-dependent increase in HSF1 transcriptional activity and recovery of luciferase activity. TRC051384 results in 60% inhibition at 6.25 μM and 90% inhibition at 12.5 μM of LPS-induced TNF-α expression in differentiated THP-1 cell line[1].
|
In Vivo |
Treatment with TRC051384 significantly reduces stroke associated neuronal injury (87% reduction in area of penumbra recruited to infarct, and 25% reduction in brain edema) and disability in a rat model of transient ischemic stroke even when administered 8 hours post onset of ischemia. Significant improvement in survival (50% by day2 and 67.3% by day 7) is observed with TRC051384 treatment initiated at 4 hours after ischemia onset. Induction of HSP70 by TRC051384 involves HSF1 activation and results in elevated chaperone and anti-inflammatory activity[1].
|
Cell Assay |
HeLa cell transiently co-transfected with heat shock elements-luciferase reporter and normalization vector, β-galactosidase are treated with vehicle or TRC051384 (12.5 and 25 μM) for 4 hours. Cell lysates are then prepared and analyzed for luciferase and β-galactosidase activity[1].
|
Animal Admin |
Rats: Injured hemispheres from vehicle treated animals and TRC051384 treated animals are collected at 10-hour post-initiation of tMCAo. Total RNA from each brain sample is extracted followed by cDNA preparation. Each sample of cDNA is analyzed[1].
|
References |
[1]. Mohanan A, et al. Delayed intervention in experimental stroke with TRC051384--a small molecule HSP70 inducer. Neuropharmacology. 2011 May;60(6):991-9.
|